調査レポート | • レポートコード：QYR2104Z4584 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、125ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、ファーマージングのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（Tier 1、Tier 2、Tier 3）、用途別市場規模（肺がん、乳がん、慢性骨髄性白血病、リンパ腫、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・ファーマージングの市場動向 ・企業の競争状況、市場シェア ・ファーマージングの種類別市場規模（Tier 1、Tier 2、Tier 3） ・ファーマージングの用途別市場規模（肺がん、乳がん、慢性骨髄性白血病、リンパ腫、その他） ・ファーマージングの北米市場規模2016-2027（アメリカ、カナダ） ・ファーマージングのヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・ファーマージングのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・ファーマージングの中南米市場規模2016-2027（メキシコ、ブラジル） ・ファーマージングの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer、Sanofi、GlaxoSmithKline、AstraZeneca、Novartis、Johnson & Johnson、F. Hoffmann-La Roche、Eli Lilly、Boehringer Ingelheim、Novo Nordisk、AbbVie、Sun Pharmaceutical、Teva Pharmaceutical Industries、Mitsubishi Tanabe Pharma、Bristol-Myers Squibb、Kyowa Hakko Kirin、CSL Behring、Takeda、Amgen、Bayer、Biogen、Eisai、Daiichi Sankyo、Dainippon Sumitomo Pharma） ・結論 |
Market Analysis and Insights: Global Pharmerging Market
The global Pharmerging market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Pharmerging market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Pharmerging market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Pharmerging market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Pharmerging market.
Global Pharmerging Scope and Market Size
Pharmerging market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Pharmerging market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Tier 1
Tier 2
Tier 3
Segment by Application
Lung Cancer
Breast Cancer
Chronic Myeloid Leukemia
Lymphomas
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Pfizer
Sanofi
GlaxoSmithKline
AstraZeneca
Novartis
Johnson & Johnson
F. Hoffmann-La Roche
Eli Lilly
Boehringer Ingelheim
AstraZeneca
Novartis
Sun Pharmaceutical
Teva Pharmaceutical Industries
Mitsubishi Tanabe Pharma
Bristol-Myers Squibb
Kyowa Hakko Kirin
CSL Behring
Takeda
Amgen
Bayer
Biogen
Eisai
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmerging Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Tier 1
1.2.3 Tier 2
1.2.4 Tier 3
1.3 Market by Application
1.3.1 Global Pharmerging Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Lung Cancer
1.3.3 Breast Cancer
1.3.4 Chronic Myeloid Leukemia
1.3.5 Lymphomas
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Pharmerging Market Perspective (2016-2027)
2.2 Pharmerging Growth Trends by Regions
2.2.1 Pharmerging Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Pharmerging Historic Market Share by Regions (2016-2021)
2.2.3 Pharmerging Forecasted Market Size by Regions (2022-2027)
2.3 Pharmerging Industry Dynamic
2.3.1 Pharmerging Market Trends
2.3.2 Pharmerging Market Drivers
2.3.3 Pharmerging Market Challenges
2.3.4 Pharmerging Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmerging Players by Revenue
3.1.1 Global Top Pharmerging Players by Revenue (2016-2021)
3.1.2 Global Pharmerging Revenue Market Share by Players (2016-2021)
3.2 Global Pharmerging Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Pharmerging Revenue
3.4 Global Pharmerging Market Concentration Ratio
3.4.1 Global Pharmerging Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmerging Revenue in 2020
3.5 Pharmerging Key Players Head office and Area Served
3.6 Key Players Pharmerging Product Solution and Service
3.7 Date of Enter into Pharmerging Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmerging Breakdown Data by Type
4.1 Global Pharmerging Historic Market Size by Type (2016-2021)
4.2 Global Pharmerging Forecasted Market Size by Type (2022-2027)
5 Pharmerging Breakdown Data by Application
5.1 Global Pharmerging Historic Market Size by Application (2016-2021)
5.2 Global Pharmerging Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Pharmerging Market Size (2016-2027)
6.2 North America Pharmerging Market Size by Type
6.2.1 North America Pharmerging Market Size by Type (2016-2021)
6.2.2 North America Pharmerging Market Size by Type (2022-2027)
6.2.3 North America Pharmerging Market Size by Type (2016-2027)
6.3 North America Pharmerging Market Size by Application
6.3.1 North America Pharmerging Market Size by Application (2016-2021)
6.3.2 North America Pharmerging Market Size by Application (2022-2027)
6.3.3 North America Pharmerging Market Size by Application (2016-2027)
6.4 North America Pharmerging Market Size by Country
6.4.1 North America Pharmerging Market Size by Country (2016-2021)
6.4.2 North America Pharmerging Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Pharmerging Market Size (2016-2027)
7.2 Europe Pharmerging Market Size by Type
7.2.1 Europe Pharmerging Market Size by Type (2016-2021)
7.2.2 Europe Pharmerging Market Size by Type (2022-2027)
7.2.3 Europe Pharmerging Market Size by Type (2016-2027)
7.3 Europe Pharmerging Market Size by Application
7.3.1 Europe Pharmerging Market Size by Application (2016-2021)
7.3.2 Europe Pharmerging Market Size by Application (2022-2027)
7.3.3 Europe Pharmerging Market Size by Application (2016-2027)
7.4 Europe Pharmerging Market Size by Country
7.4.1 Europe Pharmerging Market Size by Country (2016-2021)
7.4.2 Europe Pharmerging Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Pharmerging Market Size (2016-2027)
8.2 Asia-Pacific Pharmerging Market Size by Type
8.2.1 Asia-Pacific Pharmerging Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Pharmerging Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Pharmerging Market Size by Type (2016-2027)
8.3 Asia-Pacific Pharmerging Market Size by Application
8.3.1 Asia-Pacific Pharmerging Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Pharmerging Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Pharmerging Market Size by Application (2016-2027)
8.4 Asia-Pacific Pharmerging Market Size by Region
8.4.1 Asia-Pacific Pharmerging Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Pharmerging Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Pharmerging Market Size (2016-2027)
9.2 Latin America Pharmerging Market Size by Type
9.2.1 Latin America Pharmerging Market Size by Type (2016-2021)
9.2.2 Latin America Pharmerging Market Size by Type (2022-2027)
9.2.3 Latin America Pharmerging Market Size by Type (2016-2027)
9.3 Latin America Pharmerging Market Size by Application
9.3.1 Latin America Pharmerging Market Size by Application (2016-2021)
9.3.2 Latin America Pharmerging Market Size by Application (2022-2027)
9.3.3 Latin America Pharmerging Market Size by Application (2016-2027)
9.4 Latin America Pharmerging Market Size by Country
9.4.1 Latin America Pharmerging Market Size by Country (2016-2021)
9.4.2 Latin America Pharmerging Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmerging Market Size (2016-2027)
10.2 Middle East & Africa Pharmerging Market Size by Type
10.2.1 Middle East & Africa Pharmerging Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Pharmerging Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Pharmerging Market Size by Type (2016-2027)
10.3 Middle East & Africa Pharmerging Market Size by Application
10.3.1 Middle East & Africa Pharmerging Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Pharmerging Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Pharmerging Market Size by Application (2016-2027)
10.4 Middle East & Africa Pharmerging Market Size by Country
10.4.1 Middle East & Africa Pharmerging Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Pharmerging Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Pharmerging Introduction
11.1.4 Pfizer Revenue in Pharmerging Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Pharmerging Introduction
11.2.4 Sanofi Revenue in Pharmerging Business (2016-2021)
11.2.5 Sanofi Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Details
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Pharmerging Introduction
11.3.4 GlaxoSmithKline Revenue in Pharmerging Business (2016-2021)
11.3.5 GlaxoSmithKline Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Details
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Pharmerging Introduction
11.4.4 AstraZeneca Revenue in Pharmerging Business (2016-2021)
11.4.5 AstraZeneca Recent Development
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Pharmerging Introduction
11.5.4 Novartis Revenue in Pharmerging Business (2016-2021)
11.5.5 Novartis Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Details
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Pharmerging Introduction
11.6.4 Johnson & Johnson Revenue in Pharmerging Business (2016-2021)
11.6.5 Johnson & Johnson Recent Development
11.7 F. Hoffmann-La Roche
11.7.1 F. Hoffmann-La Roche Company Details
11.7.2 F. Hoffmann-La Roche Business Overview
11.7.3 F. Hoffmann-La Roche Pharmerging Introduction
11.7.4 F. Hoffmann-La Roche Revenue in Pharmerging Business (2016-2021)
11.7.5 F. Hoffmann-La Roche Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Details
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Pharmerging Introduction
11.8.4 Eli Lilly Revenue in Pharmerging Business (2016-2021)
11.8.5 Eli Lilly Recent Development
11.9 Boehringer Ingelheim
11.9.1 Boehringer Ingelheim Company Details
11.9.2 Boehringer Ingelheim Business Overview
11.9.3 Boehringer Ingelheim Pharmerging Introduction
11.9.4 Boehringer Ingelheim Revenue in Pharmerging Business (2016-2021)
11.9.5 Boehringer Ingelheim Recent Development
11.10 Novo Nordisk
11.10.1 Novo Nordisk Company Details
11.10.2 Novo Nordisk Business Overview
11.10.3 Novo Nordisk Pharmerging Introduction
11.10.4 Novo Nordisk Revenue in Pharmerging Business (2016-2021)
11.10.5 Novo Nordisk Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Details
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Pharmerging Introduction
11.11.4 AbbVie Revenue in Pharmerging Business (2016-2021)
11.11.5 AbbVie Recent Development
11.12 Sun Pharmaceutical
11.12.1 Sun Pharmaceutical Company Details
11.12.2 Sun Pharmaceutical Business Overview
11.12.3 Sun Pharmaceutical Pharmerging Introduction
11.12.4 Sun Pharmaceutical Revenue in Pharmerging Business (2016-2021)
11.12.5 Sun Pharmaceutical Recent Development
11.13 Teva Pharmaceutical Industries
11.13.1 Teva Pharmaceutical Industries Company Details
11.13.2 Teva Pharmaceutical Industries Business Overview
11.13.3 Teva Pharmaceutical Industries Pharmerging Introduction
11.13.4 Teva Pharmaceutical Industries Revenue in Pharmerging Business (2016-2021)
11.13.5 Teva Pharmaceutical Industries Recent Development
11.14 Mitsubishi Tanabe Pharma
11.14.1 Mitsubishi Tanabe Pharma Company Details
11.14.2 Mitsubishi Tanabe Pharma Business Overview
11.14.3 Mitsubishi Tanabe Pharma Pharmerging Introduction
11.14.4 Mitsubishi Tanabe Pharma Revenue in Pharmerging Business (2016-2021)
11.14.5 Mitsubishi Tanabe Pharma Recent Development
11.15 Bristol-Myers Squibb
11.15.1 Bristol-Myers Squibb Company Details
11.15.2 Bristol-Myers Squibb Business Overview
11.15.3 Bristol-Myers Squibb Pharmerging Introduction
11.15.4 Bristol-Myers Squibb Revenue in Pharmerging Business (2016-2021)
11.15.5 Bristol-Myers Squibb Recent Development
11.16 Kyowa Hakko Kirin
11.16.1 Kyowa Hakko Kirin Company Details
11.16.2 Kyowa Hakko Kirin Business Overview
11.16.3 Kyowa Hakko Kirin Pharmerging Introduction
11.16.4 Kyowa Hakko Kirin Revenue in Pharmerging Business (2016-2021)
11.16.5 Kyowa Hakko Kirin Recent Development
11.17 CSL Behring
11.17.1 CSL Behring Company Details
11.17.2 CSL Behring Business Overview
11.17.3 CSL Behring Pharmerging Introduction
11.17.4 CSL Behring Revenue in Pharmerging Business (2016-2021)
11.17.5 CSL Behring Recent Development
11.18 Takeda
11.18.1 Takeda Company Details
11.18.2 Takeda Business Overview
11.18.3 Takeda Pharmerging Introduction
11.18.4 Takeda Revenue in Pharmerging Business (2016-2021)
11.18.5 Takeda Recent Development
11.18 Amgen
.1 Amgen Company Details
.2 Amgen Business Overview
.3 Amgen Pharmerging Introduction
.4 Amgen Revenue in Pharmerging Business (2016-2021)
.5 Amgen Recent Development
11.20 Bayer
11.20.1 Bayer Company Details
11.20.2 Bayer Business Overview
11.20.3 Bayer Pharmerging Introduction
11.20.4 Bayer Revenue in Pharmerging Business (2016-2021)
11.20.5 Bayer Recent Development
11.21 Biogen
11.21.1 Biogen Company Details
11.21.2 Biogen Business Overview
11.21.3 Biogen Pharmerging Introduction
11.21.4 Biogen Revenue in Pharmerging Business (2016-2021)
11.21.5 Biogen Recent Development
11.22 Eisai
11.22.1 Eisai Company Details
11.22.2 Eisai Business Overview
11.22.3 Eisai Pharmerging Introduction
11.22.4 Eisai Revenue in Pharmerging Business (2016-2021)
11.22.5 Eisai Recent Development
11.23 Daiichi Sankyo
11.23.1 Daiichi Sankyo Company Details
11.23.2 Daiichi Sankyo Business Overview
11.23.3 Daiichi Sankyo Pharmerging Introduction
11.23.4 Daiichi Sankyo Revenue in Pharmerging Business (2016-2021)
11.23.5 Daiichi Sankyo Recent Development
11.24 Dainippon Sumitomo Pharma
11.24.1 Dainippon Sumitomo Pharma Company Details
11.24.2 Dainippon Sumitomo Pharma Business Overview
11.24.3 Dainippon Sumitomo Pharma Pharmerging Introduction
11.24.4 Dainippon Sumitomo Pharma Revenue in Pharmerging Business (2016-2021)
11.24.5 Dainippon Sumitomo Pharma Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Pharmerging Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Tier 1
Table 3. Key Players of Tier 2
Table 4. Key Players of Tier 3
Table 5. Global Pharmerging Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Pharmerging Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Pharmerging Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Pharmerging Market Share by Regions (2016-2021)
Table 9. Global Pharmerging Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Pharmerging Market Share by Regions (2022-2027)
Table 11. Pharmerging Market Trends
Table 12. Pharmerging Market Drivers
Table 13. Pharmerging Market Challenges
Table 14. Pharmerging Market Restraints
Table 15. Global Pharmerging Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Pharmerging Market Share by Players (2016-2021)
Table 17. Global Top Pharmerging Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pharmerging as of 2020)
Table 18. Ranking of Global Top Pharmerging Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Pharmerging Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Pharmerging Product Solution and Service
Table 22. Date of Enter into Pharmerging Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Pharmerging Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Pharmerging Revenue Market Share by Type (2016-2021)
Table 26. Global Pharmerging Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Pharmerging Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Pharmerging Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Pharmerging Revenue Market Share by Application (2016-2021)
Table 30. Global Pharmerging Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Pharmerging Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Pharmerging Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Pharmerging Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Pharmerging Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Pharmerging Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Pharmerging Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Pharmerging Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Pharmerging Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Pharmerging Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Pharmerging Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Pharmerging Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Pharmerging Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Pharmerging Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Pharmerging Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Pharmerging Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Pharmerging Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Pharmerging Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Pharmerging Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Pharmerging Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Pharmerging Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Pharmerging Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Pharmerging Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Pharmerging Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Pharmerging Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Pharmerging Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Pharmerging Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Pharmerging Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Pharmerging Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Pharmerging Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Pharmerging Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Pharmerging Market Size by Country (2022-2027) & (US$ Million)
Table 62. Pfizer Company Details
Table 63. Pfizer Business Overview
Table 64. Pfizer Pharmerging Product
Table 65. Pfizer Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 66. Pfizer Recent Development
Table 67. Sanofi Company Details
Table 68. Sanofi Business Overview
Table 69. Sanofi Pharmerging Product
Table 70. Sanofi Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 71. Sanofi Recent Development
Table 72. GlaxoSmithKline Company Details
Table 73. GlaxoSmithKline Business Overview
Table 74. GlaxoSmithKline Pharmerging Product
Table 75. GlaxoSmithKline Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 76. GlaxoSmithKline Recent Development
Table 77. AstraZeneca Company Details
Table 78. AstraZeneca Business Overview
Table 79. AstraZeneca Pharmerging Product
Table 80. AstraZeneca Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 81. AstraZeneca Recent Development
Table 82. Novartis Company Details
Table 83. Novartis Business Overview
Table 84. Novartis Pharmerging Product
Table 85. Novartis Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 86. Novartis Recent Development
Table 87. Johnson & Johnson Company Details
Table 88. Johnson & Johnson Business Overview
Table 89. Johnson & Johnson Pharmerging Product
Table 90. Johnson & Johnson Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 91. Johnson & Johnson Recent Development
Table 92. F. Hoffmann-La Roche Company Details
Table 93. F. Hoffmann-La Roche Business Overview
Table 94. F. Hoffmann-La Roche Pharmerging Product
Table 95. F. Hoffmann-La Roche Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 96. F. Hoffmann-La Roche Recent Development
Table 97. Eli Lilly Company Details
Table 98. Eli Lilly Business Overview
Table 99. Eli Lilly Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 100. Eli Lilly Recent Development
Table 101. Boehringer Ingelheim Company Details
Table 102. Boehringer Ingelheim Business Overview
Table 103. Boehringer Ingelheim Pharmerging Product
Table 104. Boehringer Ingelheim Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 105. Boehringer Ingelheim Recent Development
Table 106. Novo Nordisk Company Details
Table 107. Novo Nordisk Business Overview
Table 108. Novo Nordisk Pharmerging Product
Table 109. Novo Nordisk Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 110. Novo Nordisk Recent Development
Table 111. AbbVie Company Details
Table 112. AbbVie Business Overview
Table 113. AbbVie Pharmerging Product
Table 114. AbbVie Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 115. AbbVie Recent Development
Table 116. Sun Pharmaceutical Company Details
Table 117. Sun Pharmaceutical Business Overview
Table 118. Sun Pharmaceutical Pharmerging Product
Table 119. Sun Pharmaceutical Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 120. Sun Pharmaceutical Recent Development
Table 121. Teva Pharmaceutical Industries Company Details
Table 122. Teva Pharmaceutical Industries Business Overview
Table 123. Teva Pharmaceutical Industries Pharmerging Product
Table 124. Teva Pharmaceutical Industries Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 125. Teva Pharmaceutical Industries Recent Development
Table 126. Mitsubishi Tanabe Pharma Company Details
Table 127. Mitsubishi Tanabe Pharma Business Overview
Table 128. Mitsubishi Tanabe Pharma Pharmerging Product
Table 129. Mitsubishi Tanabe Pharma Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 130. Mitsubishi Tanabe Pharma Recent Development
Table 131. Bristol-Myers Squibb Company Details
Table 132. Bristol-Myers Squibb Business Overview
Table 133. Bristol-Myers Squibb Pharmerging Product
Table 134. Bristol-Myers Squibb Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 135. Bristol-Myers Squibb Recent Development
Table 136. Kyowa Hakko Kirin Company Details
Table 137. Kyowa Hakko Kirin Business Overview
Table 138. Kyowa Hakko Kirin Pharmerging Product
Table 139. Kyowa Hakko Kirin Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 140. Kyowa Hakko Kirin Recent Development
Table 141. CSL Behring Company Details
Table 142. CSL Behring Business Overview
Table 143. CSL Behring Pharmerging Product
Table 144. CSL Behring Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 145. CSL Behring Recent Development
Table 146. Takeda Company Details
Table 147. Takeda Business Overview
Table 148. Takeda Pharmerging Product
Table 149. Takeda Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 150. Takeda Recent Development
Table 151. Amgen Company Details
Table 152. Amgen Business Overview
Table 153. Amgen Pharmerging Product
Table 154. Amgen Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 155. Amgen Recent Development
Table 156. Bayer Company Details
Table 157. Bayer Business Overview
Table 158. Bayer Pharmerging Product
Table 159. Bayer Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 160. Bayer Recent Development
Table 161. Biogen Company Details
Table 162. Biogen Business Overview
Table 163. Biogen Pharmerging Product
Table 164. Biogen Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 165. Biogen Recent Development
Table 166. Eisai Company Details
Table 167. Eisai Business Overview
Table 168. Eisai Pharmerging Product
Table 169. Eisai Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 170. Eisai Recent Development
Table 171. Daiichi Sankyo Company Details
Table 172. Daiichi Sankyo Business Overview
Table 173. Daiichi Sankyo Pharmerging Product
Table 174. Daiichi Sankyo Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 175. Daiichi Sankyo Recent Development
Table 176. Dainippon Sumitomo Pharma Company Details
Table 177. Dainippon Sumitomo Pharma Business Overview
Table 178. Dainippon Sumitomo Pharma PharmergingProduct
Table 179. Dainippon Sumitomo Pharma Revenue in Pharmerging Business (2016-2021) & (US$ Million)
Table 180. Dainippon Sumitomo Pharma Recent Development
Table 181. Research Programs/Design for This Report
Table 182. Key Data Information from Secondary Sources
Table 183. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Pharmerging Market Share by Type: 2020 VS 2027
Figure 2. Tier 1 Features
Figure 3. Tier 2 Features
Figure 4. Tier 3 Features
Figure 5. Global Pharmerging Market Share by Application: 2020 VS 2027
Figure 6. Lung Cancer Case Studies
Figure 7. Breast Cancer Case Studies
Figure 8. Chronic Myeloid Leukemia Case Studies
Figure 9. Lymphomas Case Studies
Figure 10. Other Case Studies
Figure 11. Pharmerging Report Years Considered
Figure 12. Global Pharmerging Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Pharmerging Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Pharmerging Market Share by Regions: 2020 VS 2027
Figure 15. Global Pharmerging Market Share by Regions (2022-2027)
Figure 16. Global Pharmerging Market Share by Players in 2020
Figure 17. Global Top Pharmerging Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pharmerging as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Pharmerging Revenue in 2020
Figure 19. Global Pharmerging Revenue Market Share by Type (2016-2021)
Figure 20. Global Pharmerging Revenue Market Share by Type (2022-2027)
Figure 21. North America Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Pharmerging Market Share by Type (2016-2027)
Figure 23. North America Pharmerging Market Share by Application (2016-2027)
Figure 24. North America Pharmerging Market Share by Country (2016-2027)
Figure 25. United States Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Pharmerging Market Share by Type (2016-2027)
Figure 29. Europe Pharmerging Market Share by Application (2016-2027)
Figure 30. Europe Pharmerging Market Share by Country (2016-2027)
Figure 31. Germany Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Pharmerging Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Pharmerging Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Pharmerging Market Share by Region (2016-2027)
Figure 41. China Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Pharmerging Market Share by Type (2016-2027)
Figure 49. Latin America Pharmerging Market Share by Application (2016-2027)
Figure 50. Latin America Pharmerging Market Share by Country (2016-2027)
Figure 51. Mexico Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Pharmerging Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Pharmerging Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Pharmerging Market Share by Country (2016-2027)
Figure 57. Turkey Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Pharmerging Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Pfizer Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 61. Sanofi Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 62. GlaxoSmithKline Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 63. AstraZeneca Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 64. Novartis Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 65. Johnson & Johnson Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 66. F. Hoffmann-La Roche Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 67. Eli Lilly Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 68. Boehringer Ingelheim Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 69. Novo Nordisk Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 70. AbbVie Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 71. Sun Pharmaceutical Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 72. Teva Pharmaceutical Industries Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 73. Mitsubishi Tanabe Pharma Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 74. Bristol-Myers Squibb Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 75. Kyowa Hakko Kirin Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 76. CSL Behring Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 77. Takeda Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 78. Amgen Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 79. Bayer Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 80. Biogen Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 81. Eisai Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 82. Daiichi Sankyo Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 83. Dainippon Sumitomo Pharma Revenue Growth Rate in Pharmerging Business (2016-2021)
Figure 84. Bottom-up and Top-down Approaches for This Report
Figure 85. Data Triangulation
Figure 86. Key Executives Interviewed
世界の肺がん治療薬市場規模・現状・予測（2021年-2027年） Lung Cancer Treatment Drugs are durgs used to cure lung cancer. In the coming years, it is expected that the global Lung Cancer Treatment Drugs market will advance with higher growth rate as compared to previous years. Factors such as Smoking, Rising cases of infections, Rising rates of fast growing…- 世界の肺がん用リキッドバイオプシー市場規模・現状・予測（2021年-2027年） Lung cancer liquid biopsy helps to detect the epidermal growth factor receptor (EGFR) mutation and other identified mutations, which are responsible for lung cancer. CtDNA and CTCs have been the most explored technologies for commercial applications up to the present time. Market Analysis and Insigh…
- 世界の乳がん用画像市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Breast Cancer Imaging Market The global Breast Cancer Imaging market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the report…
- 世界のトリプルネガティブ乳がん治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Triple-Negative Breast Cancer Treatment Market The global Triple-Negative Breast Cancer Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis…
- 世界の急性骨髄性白血病（AML）市場規模・現状・予測（2021年-2027年） Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical …